Masood A Shammas
Overview
Explore the profile of Masood A Shammas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samur M, Aktas Samur A, Shah P, Park J, Park J, Fulciniti M, et al.
Blood
. 2024 Nov;
145(5):520-525.
PMID: 39571146
Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy are still unclear. Here, we used...
2.
Rajput Y, Neral A, Sherwani N, Jain V, Sahu M, Paikra F, et al.
Sci Rep
. 2024 Aug;
14(1):19510.
PMID: 39174586
Unpredictable fatal outcome of COVID-19 is attributed to dysregulated inflammation. Impaired early adaptive immune response leads to late-stage inflammatory outcome. The purpose of this study was to develop biomarkers for...
3.
Akiyama M, Hideshima T, Shammas M, Hayashi T, Hamasaki M, Tai Y, et al.
Cancer Res
. 2024 Mar;
84(6):937.
PMID: 38486483
No abstract available.
4.
Kumar S, Talluri S, Zhao J, Liao C, Potluri L, Buon L, et al.
Blood
. 2023 Nov;
143(11):996-1005.
PMID: 37992230
Genomic instability contributes to cancer progression and is at least partly due to dysregulated homologous recombination (HR). Here, we show that an elevated level of ABL1 kinase overactivates the HR...
5.
Kumar S, Zhao J, Talluri S, Buon L, Mu S, Potluri L, et al.
Gastroenterology
. 2023 May;
165(2):357-373.
PMID: 37178737
Background & Aims: The purpose of this study was to identify drivers of genomic evolution in esophageal adenocarcinoma (EAC) and other solid tumors. Methods: An integrated genomics strategy was used...
6.
Samur M, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi A, Szalat R, et al.
Blood
. 2023 Jan;
141(14):1724-1736.
PMID: 36603186
High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired...
7.
Liao C, Talluri S, Zhao J, Mu S, Kumar S, Shi J, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428789
Background: In normal cells, homologous recombination (HR) is tightly regulated and plays an important role in the maintenance of genomic integrity and stability through precise repair of DNA damage. RAD51...
8.
Morelli E, Fulciniti M, Samur M, Ribeiro C, Wert-Lamas L, Henninger J, et al.
Blood
. 2022 Sep;
141(4):391-405.
PMID: 36126301
Long noncoding RNAs (lncRNAs) can drive tumorigenesis and are susceptible to therapeutic intervention. Here, we used a large-scale CRISPR interference viability screen to interrogate cell-growth dependency to lncRNA genes in...
9.
Pal J, Rajput Y, Shrivastava S, Gahine R, Mungutwar V, Barardiya T, et al.
Mol Oncol
. 2021 Nov;
16(8):1650-1660.
PMID: 34725903
Oral squamous cell carcinoma (OSCC) is often preceded by a white patch on a surface of the mouth, called oral leukoplakia (OL). As accelerated telomere length (TL) shortening in dividing...
10.
Talluri S, Samur M, Buon L, Kumar S, Potluri L, Shi J, et al.
Blood Cancer J
. 2021 Oct;
11(10):166.
PMID: 34625538
Multiple myeloma (MM) is a heterogeneous disease characterized by significant genomic instability. Recently, a causal role for the AID/APOBEC deaminases in inducing somatic mutations in myeloma has been reported. We...